Skip to main content

Advertisement

Table 2 Total healthcare resource utilization in patients with NVAF treated with dabigatran or warfarin

From: Healthcare utilization and costs for patients initiating Dabigatran or Warfarin

Outcome Dabigatran Warfarin P valueb
N 1110 1110  
Hospitalization
 Number of patients hospitalized, n (%) 284 (25.6) 332 (29.9)  
 All cause hospitalizations, n 381 475  
Mean PPPYa [SD] (95% CI) 0.92 [3.10] (0.74, 1.11) 1.13 [2.90] (0.96, 1.30) 0.0124
  Median PPPYa (25p, 75p) 0.0 (0.0, 1.0) 0.0 (0.0, 1.0)  
ER visits
 Number of patients with an ER visit, n (%) 309 (27.8) 378 (34.1)  
 All cause ER visits, n 563 780  
 Mean PPPYa [SD] (95% CI) 1.32 [4.04] (1.08, 1.56) 1.56 [3.74] (1.34, 1.78) 0.0011
  Median PPPYa (25p, 75p) 0.0 (0.0, 1.0) 0.0 (0.0, 1.6)  
Physician office visits
 Number of patients with a physician office visit, n (%) 1068 (96.2) 1084 (97.7)  
 All cause physician office visits (n) 11,571 18,765  
  Mean PPPYa [SD] (95% CI) 21.43 [17.98] (20.37, 22.49) 29.41 [18.68] (28.31, 30.51) < 0.0001
  Median PPPYa (25p, 75p) 17.0 (10.2, 27.3) 26.4 (16.5, 39.0)  
Outpatient visits
 Number of patients with an outpatient visit, n (%) 945 (85.1) 1040 (93.7)  
 All cause outpatient visits (n) 5563 13,029  
  Mean PPPYa [SD] (95% CI) 10.86 [15.44] (9.95, 11.77) 22.02 [23.37] (20.64, 23.39) < 0.0001
  Median PPPYa (25p, 75p) 6.6 (3.0, 12.4) 16.6 (6.7, 29.0)  
  1. PPPY per-patient-per-year, SD standard deviation; CI confidence interval, p percentile, ER emergency room
  2. aPPPY was calculated at the patient level (number of HCRU divided by follow-up months), and summary statistics were derived from this measure. Patients with no HCRU for a particular place of service or event are included in the calculation of PPPY since they contributed time to the denominator
  3. b P values calculated using a Wilcoxon rank-sum test